top of page
Biosciences
Offspring
Insights & Updates
Four Reasons Antibody Programs Fail Before They Reach Patients
The most successful translational strategies increasingly focus on generating human-relevant evidence earlier, when development teams still have the opportunity to refine candidate selection, optimize trial design, and reduce uncertainty before major investments are made.
Featured
Search
From Data to Decisions: Why Modular Translational Validation Is Replacing One-Size-Fits-All Drug Development
Despite unprecedented advances in genomics, AI, and high-throughput screening, clinical attrition remains stubbornly high. Roughly 90% of therapeutic candidates fail in clinical development, with late-stage failures costing individual programs hundreds of millions of dollars. The underlying issue is rarely a lack of scientific rigor. Retrospective analyses reveal that many programs advance without sufficient evidence that their biological assumptions hold true in humans. Prom
evadanielson55
Aug 114 min read
Four Reasons Antibody Programs Fail Before They Reach Patients
The most successful translational strategies increasingly focus on generating human-relevant evidence earlier, when development teams still have the opportunity to refine candidate selection, optimize trial design, and reduce uncertainty before major investments are made.
evadanielson55
Jul 144 min read
Every Failed Program Looked Promising Once
Drug discovery has always involved making high-stakes decisions before all the answers are available. The challenge for R&D leadership is determining which uncertainties are acceptable, and which are systemic liabilities capable of derailing an entire program at the clinical threshold.
evadanielson55
Jun 154 min read
bottom of page